Schizophrenia

Schizophrenia is a chronic, severe mental disorder characterised by distortions in thinking (delusions), perception (hallucinations), emotion, behaviour, and sense of self. DSM-5-TR classifies it under Schizophrenia Spectrum and Other Psychotic Disorders. The disorder typically emerges in late adolescence or early adulthood and follows a variable course. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Schizophrenia is a chronic, severe mental disorder characterised by distortions in thinking (delusions), perception (hallucinations), emotion, behaviour, and sense of self. DSM-5-TR classifies it under Schizophrenia Spectrum and Other Psychotic Disorders. The disorder typically emerges in late adolescence or early adulthood and follows a variable course. Positive symptoms (hallucinations, delusions, disorganised speech/behaviour), negative symptoms (avolition, alogia, anhedonia, flat affect, asociality), and cognitive impairment contribute to substantial disability. Schizophrenia affects how a person thinks, feels, and perceives reality, often leading to significant challenges in daily functioning and relationships. Early treatment improves outcomes; recovery is possible with medication, therapy, and support. This document is for psychoeducation only.

Positive symptoms (additions or distortions of normal experience): Delusions are fixed false beliefs held despite clear evidence to the contrary—commonly persecutory (someone is harming or plotting against the person), referential (believing neutral events like TV or radio refer directly to them), or grandiose. Hallucinations are perceptions without an external stimulus; auditory hallucinations (hearing voices) are most common, often voices commenting on the person's actions or conversing with each other. Disorganised thinking shows as derailment (thoughts slip off track), tangentiality (going off on tangents), or incoherence (incomprehensible speech). Grossly disorganised or abnormal motor behaviour includes unpredictable agitation, odd posturing, or catatonia (rigidity, mutism, or purposeless overactivity). Negative symptoms (reductions or absences of normal function): Diminished emotional expression (flat affect) means reduced facial expression, eye contact, and vocal inflection. Avolition is reduced motivation to initiate or persist in goal-directed activities. Alogia refers to reduced speech output and spontaneous conversation. Anhedonia is diminished ability to experience pleasure. Asociality is lack of interest in social relationships. Negative symptoms often persist between psychotic episodes and strongly predict functional outcome and quality of life. Cognitive symptoms: Deficits in attention, working memory, executive function (planning, organising, mental flexibility), processing speed, and social cognition (reading others' emotions and intentions). These cognitive problems contribute to disability as much as positive and negative symptoms.

Genetic: Heritability is among the highest in psychiatry at approximately 80%. First-degree relatives have about a 10% risk of developing schizophrenia compared with ~1% in the general population. Multiple common and rare genetic variants contribute—including genes involved in the complement pathway (immune function in the brain), dopamine signalling, and glutamate transmission. No single "schizophrenia gene" exists; many genes each contribute a small amount of risk. Environmental: Obstetric complications (e.g. infection, malnutrition, hypoxia during pregnancy or birth) slightly increase risk. Being born or raised in urban settings, migration (especially to a different country or culture), and childhood trauma (abuse, neglect) are associated with higher risk. Cannabis use, especially high-potency THC products and use during adolescence, substantially increases risk and may precipitate onset in vulnerable individuals. Age and sex: Peak onset is 15–25 years in males and slightly later (mid-20s to early 30s) in females. Earlier onset is often associated with more severe illness course.

Dopamine hypothesis: mesolimbic hyperdopaminergia (positive symptoms), mesocortical hypodopaminergia (negative/cognitive). Glutamate: NMDA receptor hypofunction (ketamine model). Neurodevelopmental: early brain insults and aberrant synaptic pruning in adolescence. Neuroinflammation and oxidative stress are increasingly implicated.

Lifetime prevalence ~0.3–0.7%; similar across cultures. Slightly more common in males; earlier onset in males. Onset typically late teens to early 30s. Substantial morbidity: high rates of unemployment, homelessness, and medical comorbidity.

Structural brain changes: Ventricular enlargement (fluid-filled spaces in the brain), reduced grey matter volume especially in temporal lobes, frontal cortex, and hippocampus. Hippocampal volume reduction is often present at first episode and may progress. These changes partly reflect abnormal neurodevelopment and possible accelerated ageing. Functional changes: Altered connectivity between brain regions—the default mode network (active during self-reflection) may be overactive; salience network (detecting important stimuli) may misfire, perhaps contributing to delusions that ordinary events feel intensely significant; executive networks show reduced connectivity. Dopamine D2 receptor occupancy by antipsychotics correlates with antipsychotic response—blocking excess dopamine in certain pathways reduces positive symptoms.

At the same time, other brain regions, especially the frontal lobes that help with planning and motivation, may be underactive—explaining why it can be hard to get started, feel pleasure, or connect with others. Brain scans show that some areas are smaller or work differently than in people without the illness. Antipsychotic medications help by reducing the overactive dopamine signal. This is not a character flaw or weakness—it is a brain-based condition that responds to treatment. With the right support, many people with schizophrenia can manage symptoms and lead fulfilling lives.

Psychiatric interview: onset and course of positive/negative/cognitive symptoms; substance use; family history; safety (suicide, aggression). Mental status: thought form and content, perception, affect, behaviour. Physical and neurological exam to rule out medical causes of psychosis. Rating scales: PANSS, BPRS, SANS, SAPS.

DSM-5-TR: A. Two or more of: delusions, hallucinations, disorganised speech, disorganised/catatonic behaviour, negative symptoms (at least one must be delusions, hallucinations, or disorganised speech). B. Duration: significant portion of ≥1 month (or less if treated); continuous signs ≥6 months including prodrome/residual. C. Rule out schizoaffective and mood disorder with psychotic features. D. Not attributable to substance or medical condition. Specifiers: first episode/acute/multiple episodes; with/without catatonia; current severity.

Structured interviews: SCID-5, MINI. Scales: PANSS (positive/negative/general), BPRS. Cognitive screening: MoCA, MATRICS. Labs and imaging to exclude substance-induced or medical psychosis (CMP, CBC, TSH, B12, urine toxicology, brain MRI/CT when indicated).

Schizoaffective disorder: mood episodes concurrent with psychosis and psychotic symptoms in absence of prominent mood. Delusional disorder: non-bizarre delusions only, no prominent hallucinations or disorganised behaviour. Mood disorder with psychotic features: psychosis only during mood episodes. Substance/medication-induced psychotic disorder: temporal link to substance. Medical: delirium, CNS infection, tumour, epilepsy, autoimmune encephalitis.

Antipsychotic medication: First-line treatment; second-generation (atypical) antipsychotics (e.g. risperidone, olanzapine, quetiapine, aripiprazole, paliperidone) are generally preferred for better tolerability and lower risk of movement side effects. Clozapine is reserved for treatment-resistant schizophrenia (insufficient response after two adequate trials of other antipsychotics); it requires blood monitoring for agranulocytosis. Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse in people who struggle with daily oral medication. Medication should be continued for at least 12–24 months after first episode; longer or indefinite

maintenance is often needed for recurrent illness. Psychosocial interventions: CBT for psychosis (CBTp) helps manage persistent delusions and hallucinations. Family psychoeducation improves outcomes by reducing stress and improving adherence. Supported employment helps people return to work. Assertive community treatment (ACT) provides intensive outreach for those with severe illness. Skills training addresses social and daily living skills. Coordinated specialty care (CSC) programmes combine medication, therapy, family support, and case management for first-episode psychosis.

Outcome is variable: approximately 20% achieve a good long-term outcome with minimal residual symptoms; many have an episodic course with periods of stability and relapse; a significant minority have a more chronic course. Negative and cognitive symptoms often persist even when positive symptoms are controlled and contribute to disability. Suicide risk is approximately 5–10% over the lifetime; risk is highest in the early years after diagnosis. Better prognosis is associated with later onset, female sex, good premorbid social and occupational function, shorter duration of untreated psychosis, early effective treatment, absence of substance use, and good family support.

Suicide: approximately 5–10% of people with schizophrenia die by suicide over the lifetime; risk is highest in the first few years after diagnosis and during psychotic relapses. Self-harm and non-fatal attempts are more common. Substance use: alcohol, cannabis, and nicotine use are prevalent and worsen psychotic symptoms, reduce medication response, and increase relapse. Medical morbidity: antipsychotics contribute to metabolic syndrome (weight gain, diabetes, dyslipidaemia), cardiovascular risk, and movement disorders; lifestyle factors (sedentary habits, poor nutrition, smoking) compound these risks. Victimisation: people with schizophrenia face elevated rates of assault, exploitation, and abuse. Homelessness and incarceration occur disproportionately, often due to untreated illness, lack of housing support, and criminalisation of psychotic behaviour. Social isolation, unemployment, and poverty further worsen outcomes.

Early intervention during the prodrome (CBTp, low-dose antipsychotics in selected high-risk cases) may delay or reduce the first psychotic episode. Coordinated specialty care (CSC) programmes for first-episode psychosis improve outcomes when treatment begins quickly. Patient and family education: schizophrenia is a biological brain condition, not a character flaw or result of bad parenting. Medication adherence greatly reduces relapse; stopping medication without medical advice leads to high relapse rates. Avoiding cannabis and other substances improves symptom control and prognosis. Family support and psychoeducation reduce stress and improve engagement. Recognising early warning signs of relapse (sleep disturbance, withdrawal, increased preoccupation) allows prompt intervention.

Emil Kraepelin (1893) described "dementia praecox"—a progressive decline beginning in youth. Eugen Bleuler (1911) coined "schizophrenia" (split mind), emphasising fragmented thinking rather than dementia. DSM-III (1980) introduced operationalised criteria, separating schizophrenia from mood disorders. Second-generation (atypical) antipsychotics emerged in the 1990s, offering better tolerability for positive symptoms. Clozapine remains the gold standard for treatment-resistant schizophrenia. Deinstitutionalisation from the 1960s onward shifted care to the community, though adequate resources remain lacking in many areas. Recovery-oriented care now emphasises hope, meaningful roles, and quality of life alongside symptom management.

Stigma remains a major barrier to care and social inclusion. Misconceptions that people with schizophrenia are violent or unpredictable persist despite evidence that most violence associated with the disorder is linked to substance use or untreated psychosis. Deinstitutionalisation shifted care from hospitals to community settings, but inadequate housing, case management, and supported employment leave many without adequate support. Advocacy organisations (NAMI, MHA, Rethink Mental Illness) promote awareness, parity in insurance coverage, and anti-stigma campaigns. Cultural variations exist in symptom expression, family response, and help-seeking; culturally sensitive assessment and treatment improve engagement.

Genetics (GWAS, rare variants), neuroimaging biomarkers, digital phenotyping, novel antipsychotics with different mechanisms, cognitive remediation, early intervention.

APA. (2022). DSM-5-TR. APA Publishing. Sadock BJ, et al. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls. Schizophrenia. NCBI Bookshelf.

NIMH Schizophrenia: https://www.nimh.nih.gov/health/topics/schizophrenia StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK539864/ Note: Educational only. Not a substitute for professional care.